Please assess the completion status of the following clinical trial:

Trial Title: Long-Term, Open Label Atomoxetine Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be at least 6 years old but less than 18 years old when enrolled in first atomoxetine study~* Must meet the study criteria for ADHD~* Must be willing to have blood drawn and to complete other test required for this study~Exclusion Criteria:~* allergic to more than 1 kind of medicine or have had multiple bad reactions to any drug~* taking certain medicines that could interact with atomoxetine~* plan to move too far away from a doctor participating in this study in the next 5 years~* current or past history of any of the following: alcohol or drug abuse within the past 3 months, bipolar I or II disorder, high blood pressure, organic brain disease or seizures, psychosis, other disorders or conditions diagnosed by a doctor that might make you unsuitable to participate in this study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Atomoxetine (Type: EXPERIMENTAL): Atomoxetine-naive patients will have an acute titration to a stable dose, atomoxetine experienced patients whose therapy has been interrupted with be rapidly titrated to their previously established stable dose, and atomoxetine patients on a known stable dose may continue treatment at that dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).